ArticleLaboratory investigation; a journal of technical methods and pathology2008
Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model.
Article in Laboratory investigation; a journal of technical methods and pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.Acta parasitologica · 2021Pooled it
- In Vitro and In Silico Assessments of Curcuminoids and Turmerones fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.Beilstein journal of nanotechnology · 2024Review
- Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Energy Homeostasis of Dairy Animals: Exploiting Their Modulation through Nutrigenomic Interventions.International journal of molecular sciences · 2021Review
- Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.ACS biomaterials science & engineering · 2021Review
- Effects of Curcumin and Its Analogues on Infectious Diseases.Advances in experimental medicine and biology · 2021Review
- Curcumin in Osteosarcoma Therapy: Combining With Immunotherapy, Chemotherapeutics, Bone Tissue Engineering Materials and Potential Synergism With Photodynamic Therapy.Frontiers in oncology · 2021Review
- Nano-curcumin's suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression.Breast cancer (Dove Medical Press) · 2019Article
- Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations.Cancer letters · 2018Article
- Isolation and Structural Characterization of Bioactive Molecules on Prostate Cancer from Mayan Traditional Medicinal Plants.Pharmaceuticals (Basel, Switzerland) · 2018Article
- Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitisRSC advances · 2018Article
- Epidermal PPARγ influences subcutaneous tumor growth and acts through TNF-α to regulate contact hypersensitivity and the acute photoresponse.Oncotarget · 2017Article
- Leishmania infantum lipophosphoglycan induced-Prostaglandin EScientific reports · 2017Article
- Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.Antimicrobial agents and chemotherapy · 2017Article
- Curcumin Ameliorates Furazolidone-Induced DNA Damage and Apoptosis in Human Hepatocyte L02 Cells by Inhibiting ROS Production and Mitochondrial Pathway.Molecules (Basel, Switzerland) · 2016Article
- Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy.Colloids and surfaces. B, Biointerfaces · 2015Article
- Formulation of nanotized curcumin and demonstration of its antimalarial efficacy.International journal of nanomedicine · 2014Article
- Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.Current neuropharmacology · 2013Article
- PPAR activation induces M1 macrophage polarization via cPLA₂-COX-2 inhibition, activating ROS production against Leishmania mexicana.BioMed research international · 2013Article
- Differential modulation of intracellular survival of cytosolic and vacuolar pathogens by curcumin.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation is considered the underlying cause of numerous disorders, and the practice of taking antiinflammatories as diet supplements has become increasingly prevalent. This study addresses the bioavailablity of a well-established dietary antiinflammatory, curcumin, and examines its effect on adaptive immunity. Visceral leishmaniasis is a major parasitic disease which protection relies on cell-mediated immunity and production of nitric oxide. We found that long-term, low-dose, oral consumption of curcumin activates peroxisome proliferator-activated receptor-gamma, deactivates type 1 response, inhibits inducible nitric oxide synthase, and interferes with adaptive immunity to exacerbate the pathogenesis of Leishmania donovani infection in vivo. These in vivo effects can be correlated to activities on infected residential macrophages in vitro. Therefore, when reactive radicals generated from inflammation play the dominant role in elimination of pathogens, excessive use of the antioxidative supplements may compromise microbial defense. Nonetheless, it should be noted with equal importance that our finding, conversely, also strengthens the prospect that curcumin may alleviate type 1 response disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.